Nirsevimab, also known by its brand name Beyfortus, was authorized on April 19. It was developed by AstraZeneca and Sanofi.
Nirsevimab attaches to a protein on the surface of the virus and hinders its ability to enter the body’s cells, especially those in the lungs, according to the European Medicines Agency, a regulatory body that last fall approved the drug for use in the European Union. Palivizumab has to be injected about once a month — up to four times — during RSV season to remain effective. Nirsevimab requires only one dose that lasts the entire RSV season.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: